Summary
Sequel MedTech and Abbott partner to integrate CGM technology with automated insulin delivery. This collaboration aims to enhance diabetes management by combining Sequel’s twiist AID system with Abbott’s FreeStyle Libre 3 Plus sensor. The integration offers personalized, precise, and user-friendly diabetes care, potentially transforming the lives of individuals with type 1 diabetes.
Safeguard patient information with TrueNASs self-healing data technology.
** Main Story**
Okay, so Sequel MedTech and Abbott just announced a partnership, and honestly, it’s a pretty big deal for diabetes care. They’re teaming up to bring together continuous glucose monitoring (CGM) and automated insulin delivery (AID) systems. What does that mean for people with diabetes? Well, it could mean a real game-changer in how they manage their condition. I mean, we’re talking about combining Sequel’s twiist AID system with Abbott’s FreeStyle Libre 3 Plus sensor. Sounds techy, right? But the idea is simple: a more personalized, easier-to-use approach to diabetes management.
The Power of Integration: It’s All About Precision
Let’s dive into what makes this combo so promising. Sequel’s twiist AID system is unique, it’s the first system that actually measures the insulin volume delivered with each micro-dose. Think of it as having an incredibly precise scale for every tiny bit of insulin. This accuracy can really make a difference, for instance the system alerts users faster if there’s a potential blockage, which could prevent some nasty complications. Plus, they’re using something called iiSure Technology, four checkpoints that make sure the insulin delivery is spot-on. You can see how that would give users a lot more confidence in their treatment.
And then there’s the algorithm: Tidepool Loop, automatically adjusting basal insulin based on real-time CGM data and predictions. I remember when I first started in this field, we were still using finger prick tests multiple times a day, and manual insulin injections, the advancements in the technology are just incredible.
Now, about Abbott’s FreeStyle Libre 3 Plus sensor, which is well-known for being easy to use and widely available. By working with the twiist system, it provides real-time glucose readings. As a result the whole system can adjust insulin delivery based on exactly what the user needs at that moment. So, imagine less worry about sudden highs or lows, and better glucose control overall. What more could you want?
Accessibility and Affordability: Making it Available to Everyone
One of the best things about this partnership? They’re focused on making this technology accessible and affordable. This is key; I’ve seen firsthand how cost can be a huge barrier for people who need AID systems. Sequel is offering a flexible subscription model, with the first month free and subsequent months costing no more than $50 for eligible individuals with commercial insurance. That’s a huge step in the right direction.
This, combined with the ease of use of both the twiist system and the FreeStyle Libre 3 Plus sensor, well, it’s about giving more people with diabetes the ability to take control of their health. It should be something available to everyone, right?
What’s Next? A Hopeful Outlook
Okay, the integration of CGM tech and automated insulin delivery really does feel like a big move forward. I think the Sequel and Abbott partnership demonstrates a real commitment to innovation and focusing on the patient. I for one am looking forward to seeing what this means for individuals living with type 1 diabetes, hopefully giving them the tools to manage their condition with confidence, allowing them to live healthier lives.
Just a heads up, the twiist AID system with the integrated FreeStyle Libre 3 Plus sensor is expected to launch in the second quarter of 2025, that’s not too far away! You can find updates at www.twiist.com. Personally, I’m optimistic about the impact this partnership could have on the future of diabetes management. If you’re interested, like I am, keep your eyes peeled!
Be the first to comment